ArticleBMC cancer2022
New method for determining breast cancer recurrence-free survival using routinely collected real-world health data.
Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- External validation of a data-driven algorithm to identify breast cancer recurrences from administrative healthcare data.Breast (Edinburgh, Scotland) · 2026Article
- Estimating the number of people living with metastatic breast cancer: a population-based retrospective cohort study using linked health data.The Lancet regional health. Western Pacific · 2026Article
- Perioperative machine learning models with SHAP interpretation for predicting adverse outcomes in breast cancer surgery.Frontiers in surgery · 2026Article
- Exploring the recurrence and metastasis of breast invasive ductal carcinoma based on machine learning and survival analysis.Frontiers in oncology · 2026Article
- Article
- Leveraging survival analysis and machine learning for accurate prediction of breast cancer recurrence and metastasis.Scientific reports · 2025Article
- Evaluation of machine learning methods for the retrospective detection of ovarian cancer recurrences from chemotherapy data.ESMO real world data and digital oncology · 2024Article
- Adjuvant Ovarian Function Suppression in Premenopausal Hormone Receptor-Positive Breast Cancer.JAMA network open · 2024Article
- Estimated incidence of disruptions to event-free survival from non-metastatic cancers in New South Wales, Australia - a population-wide epidemiological study of linked cancer registry and treatment data.Frontiers in oncology · 2024Article
- Racial Disparities in the Ascertainment of Cancer Recurrence in Electronic Health Records.JCO clinical cancer informatics · 2023Article
- Direct-to-Implant Breast Reconstruction After Unilateral and Bilateral Mastectomy: Cross-Sectional Study of Patient Satisfaction and Quality of Life with BREAST-Q.Aesthetic plastic surgery · 2023Article
- Bias and Class Imbalance in Oncologic Data-Towards Inclusive and Transferrable AI in Large Scale Oncology Data Sets.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn cancer survival analyses using population-based data, researchers face the challenge of ascertaining the timing of recurrence. We previously developed algorithms to identify recurrence of breast cancer. This is a follow-up study to detect the timing of recurrence.
methodsHealth events that signified recurrence and timing were obtained from routinely collected administrative data. The timing of recurrence was estimated by finding the timing of key indicator events using three different algorithms, respectively. For validation, we compared algorithm-estimated timing of recurrence with that obtained from chart-reviewed data. We further compared the results of cox regressions models (modeling recurrence-free survival) based on the algorithms versus chart review.
resultsIn total, 598 breast cancer patients were included. 121 (20.2%) had recurrence after a median follow-up of 4 years. Based on the high accuracy algorithm for identifying the presence of recurrence (with 94.2% sensitivity and 79.2% positive predictive value), the majority (64.5%) of the algorithm-estimated recurrence dates fell within 3 months of the corresponding chart review determined recurrence dates. The algorithm estimated and chart-reviewed data generated Kaplan-Meier (K-M) curves and Cox regression results for recurrence-free survival (hazard ratios and P-values) were very similar.
conclusionThe proposed algorithms for identifying the timing of breast cancer recurrence achieved similar results to the chart review data and were potentially useful in survival analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.